-+ 0.00%
-+ 0.00%
-+ 0.00%

Fosun Pharmaceutical (600196.SH): Compound polyethylene glycol (3350) electrolyte dispersion received registration approval

Zhitongcaijing·08/03/2026 08:49:03
Listen to the news

Zhitong Finance App News, Fosun Pharmaceutical (600196.SH) issued an announcement. Recently, the company's holding subsidiary Suzhou Futaba Pharmaceutical Co., Ltd.'s application for drug registration relating to the electrolyte dispersion of compound polyethylene glycol (3350) was approved by the State Drug Administration. The approved indications are (1) to treat chronic constipation in children aged 1 to 11; (2) to treat fecal congestion in children aged 5 to 11, that is, intractable constipation accompanied by accumulation of fecal masses in the rectum and/or colon.

The drug has now been approved for marketing, which will further enrich the Group's product line.